In vitroActivation of B-CLL Cells
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 5 (sup1) , 13-19
- https://doi.org/10.3109/10428199109103373
Abstract
Apart from surface Ig receptors, a variety of membrane molecules have now been described to deliver activation and progression signals to human B cells. Among them, CD40 antigen is likely to play a crucial role in the antigen-dependent maturation process. Recent studies performed in the laboratory have established that presentation of anti-CD40 mAbs in a crosslinked fashion by mouse Ltk(-) cells stably expressing human FcyRII/CDw32, allowed normal human B cells to enter into sustained proliferation. In their overwhelming majority, B-CLL cells are positive for CD40 expression. We have therefore examined the capacity of purified B-CLL cells to be stimulated by various cytokines for growth and differentiation, following crosslinking of slgs or CD40 antigen. In most B-CLL specimens studied, IL-2 was the sole factor, among a wide panel of cytokines tested, which reproducibly and significantly induced proliferation of leukemic B cells activated with anti-Ig reagents (SAC or anti-IgM antibodies). Unlike normal B cells, the great majority of anti-Ig activated B-CLL cells failed to proliferate in response to IL-4. In this activation system, IL-4 profoundly suppressed the IL-2 driven proliferation of B-CLL. An opposite pattern of growth-response was obtained following ligation of CD40 since IL-4 elicited proliferation of B-CLL whereas the growth-promoting effect of IL-2 was reduced. Under these culture conditions, IL-4 and IL-2 displayed additive effects on leukemic B cell growth. Surprisingly, IL-4 combined with anti-CD40 mAb allowed activation of certain leukemia specimens otherwise refractory to other stimulatory signals. Most B-CLL samples were induced for IgM synthesis upon SAC stimulation. This Ig response was potentiated by IL-2 and antagonized by IL-4. Anti-CD40 mAb used alone or in combination with cytokines (IL1-IL6, IFNγ, TNFα, TGFβ) failed to induce Ig secretion from B-CLL. No evidence for Ig isotype switching was obtained with the cytokines listed above, whatever the mode of B-CLL activation. Taken together, our results suggest that B-CLL can be released in vitro from their apparent maturation block, by IL-2 and anti-Ig reagents or by IL-4 and immobilized anti-CD40 mAb. Additionally, the data reported here suggest that development of the agonistic and antagonistic activities of IL-4 on B cell growth and differentiation may depend upon the nature of the activation signal provided.Keywords
This publication has 13 references indexed in Scilit:
- Long-Term Human B Cell Lines Dependent on Interleukin-4 and antibody to CD40Science, 1991
- Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemiaLeukemia Research, 1990
- Interleukin 5 regulation of peritoneal Ly‐1 B lymphocyte proliferation, differentiation and autoantibody secretionEuropean Journal of Immunology, 1989
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- Interleukin (IL) 4 counteracts the helper effect of IL 2 on antigen‐activated human B cellsEuropean Journal of Immunology, 1989
- Structure, Function, And Genetics Of Human B Cell-Associated Surface MoleculesAdvances in Cancer Research, 1989
- Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.The Journal of Experimental Medicine, 1988
- Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells.The Journal of Experimental Medicine, 1988
- Normal, Autoimmune, and Malignant CD5+ B Cells: The LY-1 B Lineage?Annual Review of Immunology, 1988
- Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1982